Royalty Pharma plc Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Royalty Pharma plc (RPRX) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$34.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-05
- Royalty Pharma plc debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was -$34.88M.
- Royalty Pharma plc debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was -$6.68M.
- Royalty Pharma plc debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-12-31 was $24.08M, a 52.79% decline year-over-year.
- Royalty Pharma plc debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $52.48M, a 9.02% decline year-over-year.
- Royalty Pharma plc debt securities, available-for-sale, unrealized gain (loss) for fiscal 2025 was $45.86M, a 70.40% decline from fiscal 2024.
- Royalty Pharma plc debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was $154.91M, a 32.89% decline from fiscal 2023.
- Royalty Pharma plc debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $230.84M.
- Royalty Pharma plc debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$6.82M, a 138.16% decline from fiscal 2021.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$34.88M 10-Q · filed 2026-08-05 | -$41.56M 10-Q · filed 2026-08-05 | -$17.48M derived: sum of 3 quarters · filed 2026-08-05 | $35.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$6.68M 10-Q · filed 2026-05-06 | $17.40M derived: sum of 2 quarters · filed 2026-05-06 | $69.88M derived: sum of 3 quarters · filed 2026-05-06 | $42.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $24.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $76.56M derived: sum of 2 quarters · filed 2026-02-11 | $49.14M derived: sum of 3 quarters · filed 2026-08-05 | $45.86M 10-K · filed 2026-02-11 |
| 2025-09-30 | $52.48M 10-Q · filed 2025-11-05 | $25.06M derived: sum of 2 quarters · filed 2026-08-05 | $21.78M 10-Q · filed 2025-11-05 | $72.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$27.42M 10-Q · filed 2026-08-05 | -$30.70M 10-Q · filed 2026-08-05 | $20.30M derived: sum of 3 quarters · filed 2026-08-05 | $77.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$3.28M 10-Q · filed 2026-05-06 | $47.73M derived: sum of 2 quarters · filed 2026-05-06 | $105.41M derived: sum of 3 quarters · filed 2026-05-06 | $105.20M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $51.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $108.69M derived: sum of 2 quarters · filed 2026-02-11 | $108.49M derived: sum of 3 quarters · filed 2026-02-11 | $154.91M 10-K · filed 2026-02-11 |
| 2024-09-30 | $57.68M 10-Q · filed 2025-11-05 | $57.48M derived: sum of 2 quarters · filed 2025-11-05 | $103.90M 10-Q · filed 2025-11-05 | $212.24M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | -$200.00K 10-Q · filed 2025-08-06 | $46.22M 10-Q · filed 2025-08-06 | $154.56M derived: sum of 3 quarters · filed 2026-02-11 | $161.86M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $46.42M 10-Q · filed 2025-05-08 | $154.76M derived: sum of 2 quarters · filed 2026-02-11 | $162.06M derived: sum of 3 quarters · filed 2026-02-11 | $244.96M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $108.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $115.64M derived: sum of 2 quarters · filed 2026-02-11 | $198.54M derived: sum of 3 quarters · filed 2026-02-11 | $230.84M 10-K · filed 2026-02-11 |
| 2023-09-30 | $7.30M 10-Q · filed 2024-11-06 | $90.20M derived: sum of 2 quarters · filed 2024-11-06 | $122.50M 10-Q · filed 2024-11-06 | $17.70M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $82.90M 10-Q · filed 2024-08-08 | $115.20M 10-Q · filed 2024-08-08 | $10.40M derived: sum of 3 quarters · filed 2025-02-12 | $54.64M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $32.30M 10-Q · filed 2024-05-09 | -$72.50M derived: sum of 2 quarters · filed 2025-02-12 | -$28.26M derived: sum of 3 quarters · filed 2025-02-12 | $42.06M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$104.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$60.56M derived: sum of 2 quarters · filed 2025-02-12 | $9.76M derived: sum of 3 quarters · filed 2025-02-12 | -$6.82M 10-K · filed 2025-02-12 |
| 2022-09-30 | $44.24M 10-Q · filed 2023-11-08 | $114.56M derived: sum of 2 quarters · filed 2023-11-08 | $97.98M 10-Q · filed 2023-11-08 | $107.60M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $70.32M 10-Q · filed 2023-08-08 | $53.74M 10-Q · filed 2023-08-08 | $63.35M derived: sum of 3 quarters · filed 2024-02-15 | $48.47M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$16.58M 10-Q · filed 2023-05-09 | -$6.97M derived: sum of 2 quarters · filed 2024-02-15 | -$21.85M derived: sum of 3 quarters · filed 2024-02-15 | -$7.84M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $9.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$5.27M derived: sum of 2 quarters · filed 2024-02-15 | $8.74M derived: sum of 3 quarters · filed 2024-02-15 | $17.86M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$14.88M 10-Q · filed 2022-11-08 | -$870.00K derived: sum of 2 quarters · filed 2022-11-08 | $8.25M 10-Q · filed 2022-11-08 | $26.84M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $14.02M 10-Q · filed 2022-08-04 | $23.13M 10-Q · filed 2022-08-04 | $41.73M derived: sum of 3 quarters · filed 2023-02-15 | $41.73M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $9.12M 10-Q · filed 2022-05-05 | $27.71M derived: sum of 2 quarters · filed 2023-02-15 | $27.71M derived: sum of 3 quarters · filed 2023-02-15 | $27.71M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $18.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $18.60M derived: sum of 2 quarters · filed 2023-02-15 | $18.60M derived: sum of 3 quarters · filed 2023-02-15 | $18.60M 10-K · filed 2023-02-15 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |